Laura R. L.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 3 Randomized Open-Label Study of OP-1250 Versus Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer Post-Endocrine and CDK4/6 Inhibitor Therapy
- Phase III Evaluation of Sacituzumab Govitecan Versus Physician's Choice in HER2-Negative Breast Cancer with High Relapse Risk Post-Neoadjuvant Therapy
Data & Insights
Has run more than one trial at 16 of 217 partner sites.
Specializations
Breast Cancer Specialization
This investigator focuses on advanced therapeutic approaches for various subtypes of breast cancer, with particular emphasis on hormone receptor-positive cases.
- HER2-positive breast cancer management
- Hormone receptor-positive breast cancer treatment
- Early-stage breast cancer interventions
The investigator explores targeted therapies for breast cancer patients requiring specialized hormonal interventions.
Endocrine Therapy Research
Specialized research in endocrine therapy approaches for breast cancer treatment, including innovative therapeutic agents and treatment combinations.
- Novel endocrine therapy agents
- Adjuvant endocrine treatments
- Hormone receptor targeting strategies
The investigator works with advanced therapeutic options for hormone-dependent breast cancers.
Advanced Disease Management
Expert focus on treating metastatic breast cancer and developing therapeutic strategies for advanced disease states.
- CDK 4/6 inhibitor therapy applications
- Treatment sequencing strategies
- Advanced disease interventions
The investigator develops treatment approaches for complex and progressive breast cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.